California Regulators Move on Spot-On Flea Treatments as Bay Pollution Data Puts Frontline, Advantage and Seresto Under Scrutiny

California’s Department of Pesticide Regulation has published a draft aquatic risk assessment on topical fipronil pet products after monitoring found all eight San Francisco Bay Area wastewater treatment plants discharging fipronil and imidacloprid above aquatic invertebrate toxicity thresholds — putting the sector’s largest spot-on brands under regulatory scrutiny while leaving the orally administered isoxazoline products largely outside the debate.

Research conducted through the San Francisco Bay Regional Monitoring Program found fipronil and imidacloprid in treated effluent from all eight monitored facilities at levels exceeding US EPA chronic aquatic life benchmarks — 11 ng/L for fipronil and 10 ng/L for imidacloprid. Conventional wastewater treatment does not effectively remove either compound.

The transmission pathway is domestic. DPR studies detected fipronil in bath water from treated dogs up to 28 days after application, with residues also transferring via hand-washing, laundering of pet bedding and floor cleaning. Concentrations measured at pet-grooming facility sewer laterals were substantially higher than average catchment levels.

DPR opened a 60-day comment period on its draft memo and possible mitigation options, running from 19 December 2025 to 17 February 2026, focused specifically on topical fipronil spot-on and spray products for dogs and cats.

Brands most exposed
Fipronil: Frontline, Frontline Plus and Frontline Gold (Boehringer Ingelheim); Effipro (Virbac); PetArmor and other generics.
Imidacloprid: Advantage, Advantage II, Advantix and Advantage Multi, plus the Seresto collar (all Elanco).

Why the oral products sit outside this issue
Credelio (lotilaner, Elanco), Simparica (sarolaner, Zoetis), NexGard (afoxolaner, Boehringer Ingelheim) and Bravecto (fluralaner, MSD) belong to the isoxazoline class — chemically unrelated to fipronil or imidacloprid. Critically, they are administered orally and act systemically through the bloodstream, leaving no active residue on the coat to transfer to hands, bedding, flooring or bath water. The down-the-drain pathway that drives the Bay contamination is therefore largely absent.

The European Medicines Agency signalled in a 2023 concept paper that both topical compounds may be added to an environmental watch list.